Welcome to LookChem.com Sign In|Join Free
  • or
3-(cyclohexyloxy)-4'-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}-ethyl)-N-(methylsulfonyl)biphenyl-4-carboxamide hydrochloride is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

855478-25-0

Post Buying Request

855478-25-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

855478-25-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 855478-25-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,5,4,7 and 8 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 855478-25:
(8*8)+(7*5)+(6*5)+(5*4)+(4*7)+(3*8)+(2*2)+(1*5)=210
210 % 10 = 0
So 855478-25-0 is a valid CAS Registry Number.

855478-25-0Upstream product

855478-25-0Downstream Products

855478-25-0Relevant academic research and scientific papers

Discovery of highly potent and selective biphenylacylsulfonamide-based β3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: Part 5

Hattori, Kouji,Toda, Susumu,Imanishi, Masashi,Itou, Shinji,Nakajima, Yutaka,Washizuka, Kenichi,Araki, Takanobu,Hamashima, Hitoshi,Tomishima, Yasuyo,Sakurai, Minoru,Matsui, Shigeo,Imamura, Emiko,Ueshima, Koji,Yamamoto, Takao,Yamamoto, Nobuhiro,Ishikawa, Hirofumi,Nakano, Keiko,Unami, Naoko,Hamada, Kaori,Matsumura, Yasuhiro,Takamura, Fujiko

, p. 3063 - 3072 (2009)

As an extension of research conducted on β3-adrenergic receptor agonists as potential drugs for treating overactive bladder (OAB), novel series containing an acylsulfonamide moiety instead of the carboxylic acid moiety were evaluated. These com

Aminoalcohol derivatives

-

Page/Page column 10, (2010/02/12)

The present invention relates to a compound formula[I]: wherein X is bond, —CH2—, —O— or —NH—, R1 and R12 are each independently hydrogen, halogen, lower alkyl, etc., R2 is hydrogen or optionally substituted lower alkyl, R3 is hydrogen or an amino protective group, R4, R5 and R6 are each independently hydrogen or optionally substituted lower alkyl, R7 is -Z-R13, in which Z is bond, etc., and R13 is carboxy, lower alkoxycarbonyl, (lower alkylsulfonyl)carbamoyl or lower alkanoylsulfamoyl, R8 is —Y—R9, in which Y is bond, —CH2—, —O—, —S—, etc., and R9 is hydrogen, lower alkyl, cyclo(lower)alkyl, etc., and R11 is hydrogen, lower alkyl, lower alkoxy, etc., or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 855478-25-0